JP2024536869A - イミダゾピリダジンｉｌ－１７阻害剤化合物 - Google Patents

イミダゾピリダジンｉｌ－１７阻害剤化合物 Download PDF

Info

Publication number
JP2024536869A
JP2024536869A JP2024518884A JP2024518884A JP2024536869A JP 2024536869 A JP2024536869 A JP 2024536869A JP 2024518884 A JP2024518884 A JP 2024518884A JP 2024518884 A JP2024518884 A JP 2024518884A JP 2024536869 A JP2024536869 A JP 2024536869A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518884A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023049887A5 (https=
JP2024536869A5 (https=
Inventor
ゴードン，ディーン
エー． ロスコット，スティーブン
マッカーヴァー，ステファン
ピー． メドゥナ，スティーブン
ビー． ローラー，ティモシー
ソング，クリステン
イー． ヴァルデス，アレクサンダー
ウー，ドンペイ
シュー，シャオファ
イー． ハンナ，ルーク
シー． ビーヘナ，ダグラス
ディー． ゴールドバーグ，スティーブン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024536869A publication Critical patent/JP2024536869A/ja
Publication of JPWO2023049887A5 publication Critical patent/JPWO2023049887A5/ja
Publication of JP2024536869A5 publication Critical patent/JP2024536869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024518884A 2021-09-27 2022-09-26 イミダゾピリダジンｉｌ－１７阻害剤化合物 Pending JP2024536869A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US63/248,566 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US63/273,422 2021-10-29
US202263367546P 2022-07-01 2022-07-01
US63/367,546 2022-07-01
PCT/US2022/077001 WO2023049887A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (3)

Publication Number Publication Date
JP2024536869A true JP2024536869A (ja) 2024-10-08
JPWO2023049887A5 JPWO2023049887A5 (https=) 2025-09-19
JP2024536869A5 JP2024536869A5 (https=) 2025-09-19

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518884A Pending JP2024536869A (ja) 2021-09-27 2022-09-26 イミダゾピリダジンｉｌ－１７阻害剤化合物

Country Status (16)

Country Link
US (2) US12173007B2 (https=)
EP (1) EP4408847A1 (https=)
JP (1) JP2024536869A (https=)
KR (1) KR20240082369A (https=)
AU (1) AU2022349687A1 (https=)
CA (1) CA3233408A1 (https=)
CL (1) CL2024000867A1 (https=)
CO (1) CO2024003723A2 (https=)
DO (1) DOP2024000051A (https=)
IL (1) IL311751A (https=)
JO (1) JOP20240059A1 (https=)
MX (1) MX2024003772A (https=)
PE (1) PE20240935A1 (https=)
TW (1) TW202330530A (https=)
UY (1) UY39958A (https=)
WO (1) WO2023049887A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピリダジンｉｌ－１７阻害剤化合物
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
KR20250168657A (ko) * 2023-04-11 2025-12-02 다이스 알파, 인크. 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピリダジンｉｌ－１７阻害剤化合物
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
WO2023049887A1 (en) 2023-03-30
JOP20240059A1 (ar) 2024-03-26
KR20240082369A (ko) 2024-06-10
US20230143050A1 (en) 2023-05-11
MX2024003772A (es) 2024-06-19
CO2024003723A2 (es) 2024-04-18
EP4408847A1 (en) 2024-08-07
US20250109137A1 (en) 2025-04-03
UY39958A (es) 2023-04-28
DOP2024000051A (es) 2024-11-15
US12173007B2 (en) 2024-12-24
PE20240935A1 (es) 2024-04-30
TW202330530A (zh) 2023-08-01
CA3233408A1 (en) 2023-03-30
IL311751A (en) 2024-05-01
CL2024000867A1 (es) 2024-09-23
AU2022349687A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
US12173007B2 (en) Imidazopyridazine IL-17 inhibitor compounds
US11702422B2 (en) Imidazopyridazines as modulators of IL-17
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
DK3077395T3 (en) PYRROLO [2,3-D] PYRIMIDINYL, PYRROLO [2,3-B] PYRAZINYL AND PYRROLO [2,3-D] PYRIDINYL ACRYLAMIDS
US11897900B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
CN121843944A (zh) 大环化合物及其抗体-药物偶联物
JP2020143162A (ja) キナーゼ阻害剤としてのピラゾロピリミジン誘導体
JP6761815B2 (ja) ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
JP2020055859A (ja) ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン
US12215111B2 (en) Imidazopyridazine IL-17 inhibitor compounds
JP2023528334A (ja) Ｉｌ－１７ａモジュレーター
WO2018141842A1 (en) 5-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NOVEL JAK KINASE INHIBITORS
JP2026503702A (ja) 神経変性疾患の処置に有用な１－アミノ－４－フェニルフタラジン誘導体
JP7627269B2 (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
EA049269B1 (ru) Соединения ингибиторов il-17 на основе имидазопиридазина
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物
WO2025146502A1 (en) Coronavirus inhibiting compounds
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250910